By Chris Wack
Centessa Pharmaceuticals shares rose 14% to $17.19 after the company priced an underwritten public offering of 15.3 million American Depositary shares, each representing one ordinary share, at $14.75 per ADS.
The clinical-stage pharmaceutical company expects to see proceeds from this offering of $225 million.
All ADSs sold in the offering were offered by the Boston-based Centessa.
The offering is expected to close on or about Monday.
Centessa has granted the underwriters a 30-day option to buy up to an additional 2.3 million ADSs at the public offering price, less underwriting discounts and commissions.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 13, 2024 10:55 ET (14:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。